RPL9P29: A Promising Drug Target / Biomarker (G100129357)

Target Name: RPL9P29

NCBI ID: G100129357

RPL9P29

Other Name(s): ribosomal protein L9 pseudogene 29 | RPL9_17_1576 | Ribosomal protein L9 pseudogene 29

RPL9P29: A Promising Drug Target / Biomarker

The protein RPL9P29 is a key regulator of the Replication Protein complex (RPC), which is responsible for copying the genetic material of a cell in the process of cell division. RPL9P29 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. In this article, we will explore the biology of RPL9P29 and its potential as a drug target.

Structure and Function

RPL9P29 is a 29-kDa protein that contains 205 amino acid residues. It belongs to the nucleotide-binding oligomerization domain (NBO domain) family 1 (NBO1) and is characterized by a nucleotide-binding domain and a hydrophobic tail. The NBO1 domain is known for its ability to form a nucleotide-binding oligomerization complex, which allows the protein to interact with nucleotides in a specific sequence.

RPL9P29 functions as a key regulator of the Replication Protein complex (RPC), which is responsible for copying the genetic material of a cell in the process of cell division. The RPC is a complex of several proteins that includes the protein RPL9, which plays a crucial role in regulating the formation and disassembly of RPCs.

RPL9P29 plays a vital role in the regulation of DNA replication and has been implicated in various diseases. It has been shown to be involved in the development and progression of cancer, neurodegenerative diseases, and developmental disorders.

Drug Target Potential

RPL9P29 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. The NBO1 domain of RPL9P29 has been shown to be involved in the regulation of nucleotide-binding oligomerization, which may provide a novel mechanism for the development of drug targets.

In cancer, RPL9P29 has been shown to be involved in the regulation of DNA replication and has been linked to the development and progression of various types of cancer. For example, studies have shown that inhibition of RPL9P29 has anti-tumor effects in various cancer models, including breast, ovarian, and colorectal cancer.

In neurodegenerative diseases, RPL9P29 has been shown to be involved in the regulation of protein synthesis and may play a role in the development and progression of neurodegenerative diseases. For example, studies have shown that RPL9P29 is involved in the regulation of the translation of the protein huntingtin, which is a neurodegenerate protein that is known to contribute to the development of neurodegenerative diseases.

In developmental disorders, RPL9P29 has been shown to be involved in the regulation of gene expression and may play a role in the development and progression of developmental disorders. For example, studies have shown that RPL9P29 is involved in the regulation of the expression of the gene involved in the development of Down syndrome, which is a genetic disorder that affects cognitive and motor function.

Conclusion

In conclusion, RPL9P29 is a protein that has been shown to play a crucial role in the regulation of the Replication Protein complex and is involved in the development and progression of various diseases. Its NBO1 domain and its involvement in the regulation of nucleotide-binding oligomerization make it a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Further research is needed to fully understand the role of RPL9P29 in disease progression and to develop effective treatments.

Protein Name: Ribosomal Protein L9 Pseudogene 29

The "RPL9P29 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL9P29 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets